Gleason Group’s Aptose Biosciences, Inc. APTO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-4,206
| Closed | -$6.34K | – | 455 |
|
|
2026
Q2 | $6.34K | Hold |
4,206
| – | – | ﹤0.01% | 285 |
|
|
2026
Q1 | $7.02K | Hold |
4,206
| – | – | ﹤0.01% | 191 |
|
|
2025
Q4 | $6.5K | Hold |
4,206
| – | – | ﹤0.01% | 190 |
|
|
2025
Q3 | $4.96K | Hold |
4,206
| – | – | ﹤0.01% | 175 |
|
|
2025
Q2 | $3.55K | Buy |
4,206
+4,166
| +10,415% | +$7.12K | ﹤0.01% | 184 |
|
|
2025
Q1 | $126 | Sell |
40
-1
| -2% | -$5 | ﹤0.01% | 187 |
|
|
2024
Q4 | $274 | Hold |
41
| – | – | ﹤0.01% | 190 |
|
|
2024
Q3 | $500 | Hold |
41
| – | – | ﹤0.01% | 185 |
|
|
2024
Q2 | $923 | Hold |
41
| – | – | ﹤0.01% | 262 |
|
|
2024
Q1 | $2.02K | Hold |
41
| – | – | ﹤0.01% | 191 |
|
|
2023
Q4 | $3.09K | Hold |
41
| – | – | ﹤0.01% | 200 |
|
|
2023
Q3 | $3.4K | Hold |
41
| – | – | ﹤0.01% | 205 |
|
|
2023
Q2 | $5.64K | Hold |
41
| – | – | ﹤0.01% | 199 |
|
|
2023
Q1 | $11.7K | Hold |
41
| – | – | ﹤0.01% | 170 |
|
|
2022
Q4 | $10.6K | Hold |
41
| – | – | ﹤0.01% | 169 |
|
|
2022
Q3 | $11K | Hold |
41
| – | – | ﹤0.01% | 171 |
|
|
2022
Q2 | $14K | Hold |
41
| – | – | ﹤0.01% | 162 |
|
|
2022
Q1 | $25K | Buy |
+41
| New | +$22.7K | 0.01% | 143 |
|
Gleason Group's APTO Position: Q3 2026 in Review
Gleason Group sold out of Aptose Biosciences, Inc. (APTO) in Q3 2026, closing a stake of 4,206 shares — an estimated $6.34K sold.
Gleason Group first reported a position in APTO in Q1 2022 and held it in 18 quarters. The position peaked at $25K in Q1 2022. 0 funds tracked by Wall St. Rank hold APTO as of Q3 2026.
- Gleason Group reported no remaining Aptose Biosciences, Inc. position as of Q3 2026 after selling out during the quarter.
- Gleason Group sold 4,206 Aptose Biosciences, Inc. shares in Q3 2026, an estimated $6.34K.
- Gleason Group first reported a position in Aptose Biosciences, Inc. in Q1 2022 and held it in 18 quarters.
- Gleason Group's Aptose Biosciences, Inc. position peaked at $25K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q3 2026.
Based on Gleason Group's 13F filing for Q3 2026, filed 15 Oct 2026.